850-060-0212

Education Requirements for Injections/IV Chelation Therapy

(1) Before using therapeutic injections or preventive injections of any substance, whether intramuscular (IM) or subcutaneous (SC) or intravenous (IV), licensee must provide proof of Board approved qualifying continuing education prior to using these applications as set forth in this rule, or proof of Board approved qualifying education received at an approved medical institution equivalent to the prescribed continuing education.

(2) Subcutaneous and intramuscular therapeutic injections require a one-time two hour qualifying education on this subject.

(3) IV therapeutic injections of vitamins or minerals require a one-time 12 hour qualifying education on this subject.

(4) Preventive injections (IM, SC, IV) require an additional one-time four hours of qualifying education in addition to the CE hours noted in OAR 850-060-0212(2) and (3).

(5) The use of any IV chelation therapy requires 12 hours of Board approved qualifying education in addition to the education required in (2), (3) and (4) of this rule.

(6) Licensee must stay current in IV chelation training. Current means licensee has completed the education and obtained a certificate of competence within the last five years.

(7) Qualifying chelation therapy education must be provided by faculty with at least five years of experience in IV chelation therapy and current training approved by the Board. The qualifying education must contain all of the following:

(a) Current/historical research on IV chelation therapy,
(b) Indications/contraindications of IV chelation therapy,
(c) IV Chelation therapy side effects and toxicity,
(d) IV Chelation therapy and practical application,
(e) IV solutions,
(f) Initial evaluation and treatment monitoring requirements,
(g) Frequency of IV treatment and remineralization,
(h) Charting requirements, standards of care, office procedures, consent to treat, nutrition and lifestyle recommendations during treatment,
(i) Heavy metal toxicity and disease,
(j) Practical on mixing and administering IV Chelation solutions,
(k) Examination for certification (exam subject to Board approval).

Stat. Auth.: ORS 685.125
Stats. Implemented: ORS 685
Hist.: BNE 6-2004, f. & cert. ef. 6-10-04; BNE 6-2005, f. & cert. ef. 8-15-05; Renumbered from 850-010-0212, BNE 8-2005, f. & cert. ef. 10-27-05; OBNM 6-2010, f. & cert. ef. 12-13-10

850-060-0215

Drug Enforcement Administration Registration

(1) Licensees may register with the United States Department of Justice for the issuance of a Drug Enforcement Administration (DEA) Number.

(2) Licensees with DEA registration have authority to prescribe from Schedules II, IIN, III, IIIN, IV and V, provided those drugs are found on the Formulary compendium, OAR 850-060-0225 or 850-060-0226.

(3) Licensees shall not prescribe from Schedules II, IIN, III, IIIN, IV and V without a current DEA registration.

Stat. Auth.: ORS 685.125
Stats. Implemented: ORS 685.145
Hist.: NE 6-1980, f. & ef. 9-11-80; NE 2-1984, f. & ef. 2-28-84; BNE 2-2004, f. & cert. ef. 4-14-04; Renumbered from 850-010-0215, BNE 8-2005, f. & cert. ef. 10-27-05; OBNM 7-2011, f. 12-15-11, cert. ef. 12-23-11

October 2016
Authority to Prescribe, Dispense, Administer, and Order

Naturopathic physicians shall be allowed to prescribe, dispense, administer, and order the following:

1. All substances recommended by the Formulary Council and approved by the Board,
2. All vitamins, minerals, trace minerals, enzymes, and food,
3. All mechanical devices, except those that require major surgical intervention,
4. All homeopathic preparations,
5. All laboratory and diagnostic procedures,
6. Antibiotics to partner(s) of patients diagnosed with a sexually transmitted disease without a patient visit by the partner of the patient for Expedited Partner Therapy (EPT) per OAR 855-041-8000 to 855-041-8005 of the Department of Human Services.

Stat. Auth.: ORS 685.125
Stats. Implemented: 685.030
Hist.: NE 2-1984, f. & ef. 2-28-84; BNE 2-2005, f. & cert. ef. 2-4-05; Renumbered from 850-010-0220, BNE 8-2005, f. & cert. ef. 10-27-05; OBNM 1-2010, f. & cert. ef. 2-16-10; OBNM 3-2010, f. & cert. ef. 5-3-10

Formulary Compendium Exclusions

The Formulary Council has approved substances as listed by classification in 850-060-0226 for use by Naturopathic physicians in accordance with professional standards of care.

1. This authority does not supersede the education and training requirement established in 850-060-0212 for administration of IV agents or any other education and training required to prescribe, dispense, administer or order all legend or controlled substances.
2. Additionally, the following substances may not be prescribed by licensees of this Board without approved specialized education and training.

(a) Barbiturates as defined in 850-060-0226(8)(D), except Phenobarbital.
(b) Systemic oncology agents with the exception of the following antineoplastic agents (oral and topical only) as found in 850-060-226(3)
   (A) 5FU;
   (B) Anastrozole;
   (C) Letrozole;
   (D) Mechlorethamine;
   (E) Megestrol;
   (F) Mercaptopurine;
   (G) Methotrexate;
   (H) Tamoxifen;
   (I) Tretinoin.
(c) General anesthetics;
(d) Oxytocics and mifepristone used as an abortifacient;
(e) Any other substance not listed in 850-060-0226 classification or meeting prior approval of the Board.

Stat. Auth.: ORS 685.125
Stats. Implemented: ORS 685.030
Hist.: OBNM 4-2016, f. & cert. ef. 10-12-16
850-060-0226
Formulary Compendium Classifications
The Formulary Council has approved the current American Hospital Formulary Service Pharmacologic-Therapeutic Classification, following pharmacologic-therapeutic classifications in addition to drugs previously approved by the Formulary Council and listed in 850-060-0225. This listing does not supersede the education and training requirement established in 850-060-0212 for administration of IV agents or the exclusions listed in 850-060-0220. The Formulary Council may consider new agents, substances and pharmacologic-therapeutic classifications for addition to this list.

(1) Antihistamine Drugs:
(a) First Generation Antihistamine Drugs:
(A) Ethanolamine Derivatives;
(B) Ethylenediamine Derivatives;
(C) Phenothiazine Derivatives;
(D) Piperazine Derivatives;
(E) Propylamine Derivatives;
(F) Miscellaneous Derivatives;
(b) Second Generation Antihistamines

(2) Anti-Infective Agents:
(a) Antihelmintics;
(b) Antibacterials:
(A) Aminoglycosides;
(B) Cephalosporins:
(i) First Generation Cephalosporins;
(ii) Second Generation Cephalosporins;
(iii) Third Generation Cephalosporins;
(iv) Fourth Generation Cephalosporins;
(C) Miscellaneous ß-Lactams;
(i) Carbacephems;
(ii) Carbapenems;
(iii) Cephamycins;
(iv) Monobactams;
(D) Chloramphenicol;
(E) Macrolides:
(i) Erythromycins;
(ii) Ketolides;
(iii) Other Macrolides;
(L) Macrolides:
(i) Erythromycins;
(ii) Ketolides;
(iii) Other Macrolides;
(L) Penicillins:
(i) Natural Penicillins;
(ii) Aminopenicillins;
(iii) Penicillinase-resistant Penicillins;
(iv) Extended-spectrum Penicillins;
(C) Quinolones;
(H) Sulfonamides;
(I) Tetraeyclines: Glycylcyclines;
(J) Antibacterials, Miscellaneous:
(i) Aminocyclitols;
(ii) Bacitracins;
(iii) Cyclic Lipopeptides;
(iv) Glycopeptides;
(v) Lincomyins;
(vi) Oxazolidinones;
(vii) Polymyxins;
(viii) Rifamycins;
(ix) Streptogramins;
(e) Antifungals:
(A) Allylamines;
(B) Azoles;
(C) Echinocandins;
(D) Polyenes;
(E) Perimidines;
(F) Antifungals, Miscellaneous;
(G) Antimycobacterials:
(A) Antituberculosis Agents;
(B) Antimycobacterials, Miscellaneous;
(e) Antivirals:
(A) Adenoviruses;
(B) Antiretrovirals:
(i) HIV Fusion Inhibitors;
(ii) HIV Protease Inhibitors;
(iii) Integrate Inhibitors;
(iv) Nonnucleoside Reverse Transcriptase
Transcriptase Inhibitors;
(a) Nucleoside and Nucleotide Reverse
Transcriptase Inhibitors;
(C) Interferons;
(D) Monoclonal Antibodies;
(E) Neuraminidase Inhibitors;
(F) Nucleosides and Nucleotides;
(G) Antivirals, Miscellaneous;
(D) Antiprotozoals:
(A) Amebicides;
(B) Antimalarials;
(C) Antiprotozoals, Miscellaneous;
(3) Antineoplastic Agents (oral and topical only)
limited to the following:
(a) 5FU;
(b) Anastrozole;
(c) Letrozole;
(d) Moclodone;
(e) Megestrol;
(f) Mercaptopurine;
(g) Methotrexate;
(h) Tamoxifen;
(i) Tretinoin.

(4) Autonomic Drugs;
(a) Parasympathomimetic (Cholinergic) Agents;
(b) Anticholinergic Agents;
Antimuscarinics/Antispasmodics;
(c) Sympathomimetic (Adrenergic) Agents;
(A) α-Adrenergic Agonists;
(B) β-Adrenergic Agonists;
(i) Non-selective β-Adrenergic Agonists;
(ii) Selective β1-Adrenergic Agonists;
(iii) Selective β2-Adrenergic Agonists;
(C) α And β-Adrenergic Agonists;
(d) Sympatholytic (Adrenergic Blocking) Agents;
(e) Skeletal Muscle Relaxants;
(A) Centrally Acting Skeletal Muscle Relaxants;
(B) Direct-acting Skeletal Muscle Relaxants;
(C) GABA-derivative Skeletal Muscle Relaxants;
(D) Neuromuscular Blocking Agents;
(E) Skeletal Muscle Relaxants, Miscellaneous;
(f) Autonomic Drugs, Miscellaneous.

(5) Blood Derivatives.

(6) Blood Formation, Coagulation, and Thrombosis;
(a) Antianemia Drugs- Iron Preparations;
(b) Antithrombotic Agents;
(A) Anticoagulants;
(i) Coumarin Derivatives;
(ii) Direct-Thrombin Inhibitors;
(iii) Heparins;
(iv) Anticoagulants, Miscellaneous;
(B) Platelet-reducing Agents;
(C) Platelet-aggregation Inhibitors;
(D) Thrombolytic Agents;
(e) Hematopoietic Agents;
(f) Hemorheologic Agents;
(g) Antihemorrhagic Agents;
(A) Antiheparin Agents;
(B) Hemostatics.

(2) Cardiovascular Drugs;
(a) Cardiac Drugs;
(B) Antihyperlipidemic Agents;
(A) Antiarrhythmic Agents;
(i) Class I Antiarrhythmics;
(ii) Class II Antiarrhythmics;
(iii) Class III Antiarrhythmics;
(iv) Class IV Antiarrhythmics;
(B) Cardiotoxic Agents;
(C) Cardiotoxic, Miscellaneous;
(b) Antilipemic Agents;
(A) Bile Acid Sequestrants;
(B) Cholesterol Absorption Inhibitors;
(C) Fibric Acid Derivatives;
(D) HMG-CoA Reductase Inhibitors;
(E) Antilipemic Agents, Miscellaneous.

(4) Hypotensive Agents;
(A) Calcium-Channel Blocking Agents;
(B) Central α-Agonists;
(C) Direct Vasodilators;
(D) Peripheral Adrenergic Inhibitors.

(4) Vasodilating Agents;
(A) Nicotinic and Nitrates;
(B) Phosphodiesterase Inhibitors;
(C) Vasodilating Agents, Miscellaneous;
(d) Vasodilating Agents, Selective Agents;
(A) α-Adrenergic Blocking Agents;
(B) β-Adrenergic Blocking Agents;
(C) Calcium-Channel Blocking Agents;
(A) Dihydropyridines;
(B) Calcium-Channel Blocking Agents,
Miscellaneous;
(i) Renin-Angiotensin-Aldosterone System Inhibitors;
(A) Angiotensin-Converting Enzyme Inhibitors;
(B) Angiotensin II Receptor Antagonists;
(C) Mineralocorticoid (Aldosterone) Receptor Antagonists;
(D) Renin Inhibitors.

(5) Central Nervous System Agents;
(a) Analgesics and Antipyretics;
(A) Nonsteroidal Anti-inflammatory Agents;
(i) Cyclooxygenase-2 (COX-2) Inhibitors;
(ii) Salicylates;
(iii) Other Nonsteroidal Anti-inflammatory Agents;
(B) Opiate Agonists;
(C) Opiate Partial Agonists;
(D) Analgesics and Antipyretics, Miscellaneous;
(b) Opiate Antagonists;
(c) Anticonvulsants;
(A) Benzodiazepines;
(B) Hydantoins;
(C) Succinimides;
(D) Anticonvulsants, Miscellaneous;
(d) Psychotherapeutic Agents;
(A) Antidepressants;
(i) Monoamine Oxidase Inhibitors;
(ii) Selective Serotonin- and Norepinephrine-
reuptake Inhibitors;
(iii) Selective Serotonin- Reuptake Inhibitors;
(iv) Serotonin Modulators;
(v) Tricyclics and Other Norepinephrine-
reuptake Inhibitors;
(vi) Antidepressants, Miscellaneous.
(B) Antipsychotics.
(e) Anorexigenic Agents and Respiratory and
Cerebral Stimulants.
(A) Amphetamines.
(B) Anorexigenic Agents and Respiratory and
Cerebral Stimulants, Miscellaneous.
(i) Anxiolytics, Sedatives, and Hypnotics does not
include Barbiturates
(A) Benzodiazepines.
(B) Anxiolytics, Sedatives, and Hypnotics.
(i) Nitrous oxide.
(g) Antimanic Agents;
(h) Antimigraine Agents: Selective Serotonin
Agonists;
(i) Antiparkinsonian Agents;
(A) Adamantanes;
(B) Anticholinergic Agents;
(C) Catechol-O-Methyltransferase (COMT)
Inhibitors;
(D) Dopamine Precursors;
(E) Dopamine Receptor Agonists;
(i) Ergot-derivative Dopamine Receptor
Agonists;
(ii) Non-ergot-derivative Dopamine Receptor
Agonists;
(F) Monoamine Oxidase B Inhibitors;
(i) Central Nervous System Agents, Miscellaneous.
9) Contraceptives (foams, devices).
10) Diagnostic Agents.
11) Disinfectants (for Agents used on objects other
than skin).
12) Electrolytic, Caloric, and Water Balance;
(a) Acidifying Agents;
(b) Alkalizing Agents;
(c) Ammonia Detoxicants;
(d) Replacements Preparations;
(e) Ion-removing Agents;
(A) Calcium-removing Agents;
(B) Potassium-removing Agents;
(C) Phosphate-removing Agents;
(D) Other Ion-removing Agents;
(f) Caloric Agents;
(g) Diuretics;
(A) Loop Diuretics;
(B) Osmotic Diuretics;
(C) Potassium-sparing Diuretics;
(D) Thiazide Diuretics;
(E) Thiazide-like Diuretics;
(F) Diuretics, Miscellaneous;
(h) Irrigation Solutions;
(i) Uricosuric Agents.
13) Enzymes.
14) Respiratory Tract Agents;
(a) Antihistamines;
(b) Antitussives;
(c) Anti-inflammatory Agents:
(A) Leukotriene Modifiers;
(B) Mast-cell Stabilizers;
(d) Expectorants;
(e) Pulmonary Surfactants;
(f) Respiratory Agents, Miscellaneous.
15) Eye, Ear, Nose, and Throat (EENT)
Preparations;
(a) Antiallergic Agents;
(b) Anti-infectives:
(A) Antibacterials;
(B) Antifungals;
(C) Antivirals;
(D) Anti-infectives, Miscellaneous.
(c) Anti-inflammatory Agents:
(A) Corticosteroids;
(B) Nonsteroidal Anti-inflammatory Agents;
(C) Anti-inflammatory Agents, Miscellaneous.
(d) Local Anesthetics;
(e) Hydratics;
(f) Mouthwashes and Gargles;
(g) Vasoconstrictors;
(h) Antihistaminic Agents:
(A) ß-adrenergic Agonists.
(D) Miotics;
(E) Prostaglandin Analogs;
(i) EENT Drugs, Miscellaneous.

(16) Gastrointestinal Drugs:
(a) Antacids and Adsorbents;
(b) Antidiarrhea Agents;
(c) Antiflatulents;
(d) Cathartics and Laxatives;
(e) Cholelitholytic Agents;
(f) Emetics;
(g) Antidiarrheals;
(h) Antiflatulents.

(A) Antihistamines;
(B) 5-HT3 Receptor Antagonists;
(C) Antiemetics, Miscellaneous.

(h) Antiulcer Agents and Acid Suppressants;
(A) Histamine H2-Antagonists;
(B) Prostaglandins;
(C) Proton pump Inhibitors;
(D) Prokinetic Agents;
(E) Anti-inflammatory Agents;
(F) GI Drugs, Miscellaneous.

(17) Gold Compounds.

(18) Heavy Metal Antagonists.
NOTE: IV administration requires education and training compliance with 850-060-0212.

(19) Endocrine Metabolic Agents:
(a) Adrenals;
(b) Androgens;
(c) Contraceptives;
(d) Corticosteroids;
(e) Estrogens and Antiestrogens;
(A) Estrogens;
(B) Estrogen-Agonists-Antagonists;
(i) Gonadotropins;
(g) Antidiabetic Agents;
(A) a-Glucosidase Inhibitors;
(B) Amylinomimetics;
(C) Biguanides;
(D) Dipeptidyl Peptidase (DPP-4) Inhibitors;
(E) Incretin Mimetics;
(F) Insulins;
(G) Meglitinides;
(H) Sulfonylureas;
(i) Thiazolidinediones;
(j) Miscellaneous.

(h) Antihypoglycemic Agents: Glycogenolytic Agents;
(i) Parathyroid;
(j) Pituitary.

(k) Somatotropin Agonists and Antagonists;
(A) Somatotropin Agonists;
(B) Somatotropin Antagonists;
(l) Progestins;
(m) Prostaglandin;
(n) Thyroid and Antithyroid Agents;
(A) Thyroid Agents;
(B) Antithyroid Agents.

(20) Local Anesthetics.

(21) Oxytocics, not to be used as an abortifacient.

(22) Serums, Toxoids, and Vaccines;
(a) Serums;
(b) Toxoids;
(c) Vaccines;

(23) Skin and Mucous Membrane Agents;
(a) Anti-infectives;
(A) Antibacterials;
(B) Antivirals;
(C) Antifungals;
(iii) Allylamines;
(ii) Azoles;
(iii) Benzylamines;
(iv) Hydroxypyridones;
(v) Polyenes;
(vi) Thiocarbamates;
(vii) Antifungals, Miscellaneous.
(D) Scabicides and Pediculicides;
(E) Local Anti-infectives, Miscellaneous;
(F) Local Anti-inflammatory Agents;
(G) Antipruritics and Local Anesthetics;
(H) Astringents;
(I) Cell Stimulants and Proliferants;
(J) Detergents;
(k) Emollients, Demulcents, and Protectants;
(l) Keratolytic Agents;
(m) Keratoplastic Agents;
(n) Depigmenting and Pigmenting Agents;
(A) Depigmenting Agents;
(B) Pigmenting Agents;
(k) Sunscreen Agents;
(l) Skin and Mucous Membrane Agents, Miscellaneous.
(24) Smooth Muscle Relaxants:
(a) Gastrointestinal Smooth Muscle Relaxants;
(b) Genitourinary Smooth Muscle Relaxants;
(c) Respiratory Smooth Muscle Relaxants.

(25) Vitamins, Minerals and Nutrients.

(26) Miscellaneous Therapeutic Agents:
(a) Alcohol Deterrents limited to the following:
   (A) Acamprosate;
   (B) Disulfiram;
   (C) Naltrexone.
(b) 5-a Reductase Inhibitors;
(c) Antidot;
(d) Antigout Agents;
(e) Biologic Response Modifiers, not to be used for systemic oncology;
(f) Bone Resorption Inhibitors;
(g) Cariostatic Agents;
(h) Complement Inhibitors;
(i) Gonadotropin-releasing Hormone Agonists;
(j) Hyaluronic Acid;
(k) Immunosuppressive Agents;
(l) Oxygen;
(m) Other Miscellaneous Therapeutic Agents limited to the following:
   (A) Alfuzosin Hydrochloride;
   (B) Drotrecogin Alfa (Activated);
   (C) Lanreotide Acetate;
   (D) Rilonacept;
   (E) Sapropterin Dihydrochloride;
   (F) Tamsulosin Hydrochloride.